Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics


The purpose of this research study is to learn if differences seen in scans before surgery match differences seen when looking at tumor samples with pathology and genetic tests. In this study we will use Magnetic Resonance Imaging [MRI] and Positron Emission Tomography [PET] scans. No direct clinical benefits will come from the results of this study.

Study Start Date

May 2014

Estimated Completion Date

May 2017


  • Procedure: PET/CT Scan
  • Procedure: MRI


  • Endocrinology: Endocrine Oncology
  • Oncology: Endocrine Oncology
  • Radiology: CT/SPECT/PET,MRI
  • Physician Assistant: Endocrinology

MeSH Terms

  • MRI
  • Ovarian Cancer
  • Ovarian Neoplasms
  • PET/CT Scan

Study ID

Memorial Sloan-Kettering Cancer Center -- 14-061



Trial ID


Study Type


Trial Phase


Enrollment Quota



Memorial Sloan-Kettering Cancer Center

Inclusion Criteria

  • ?18 years of age on the day of signing the informed consent.
  • Histologically confirmed stage III or IV high-grade serous ovarian cancer.
  • Scheduled to undergo primary debulking surgery.

Exclusion Criteria

  • Pregnant patients
  • Patients who because of general medical or psychiatric condition, or physiologic status unrelated to the presence of ovarian cancer cannot give valid informed consent
  • Patients who are unwilling or unable to undergo MRI including patients with contraindications to MRI such as the presence of cardiac pacemakers or non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc.
  • Patients with a metallic hip implant or any other metallic implant or device in the pelvis that might distort local magnetic field and compromise quality of MRI/
  • Radiotherapy to the abdomen or pelvis within 6 months of the screening visit.
  • Unresolved bowel obstruction.
  • History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with patient's participation for the full duration of the study.
  • Absence of target lesions (> 2.0 cm) on staging CT
  • Patients unlikely to be optimally debulked at surgery (tumor implants in difficult to reach places [i.e. falciform ligament or porta hepatis], suprarenal retroperitoneal lymphadenopathy)
  • Non-English speaking patients




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (2)

Study Location Distance Name Phone Email
Memorial Sloan Kettering West Harrison - West Harrison, New York 28.7 miles Evis Sala MD PhD 212-639-2179 None
Memorial Sloan Kettering Cancer Center - New York, New York 50.7 miles Evis Sala MD PhD 212-639-2179 None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.